BCV
KYTX icon

Banque Cantonale Vaudoise’s Kyverna Therapeutics KYTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Buy
33,444
+2,912
+10% +$25.9K ﹤0.01% 592
2026
Q1 		$263K Buy
+30,532
New +$254K 0.01% 595

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Banque Cantonale Vaudoise's KYTX Position: Q2 2026 in Review

Banque Cantonale Vaudoise increased its Kyverna Therapeutics (KYTX) stake by 9.5% in Q2 2026, buying an estimated $25.9K and bringing the position to 33,444 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Banque Cantonale Vaudoise first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $263K in Q1 2026. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Banque Cantonale Vaudoise held 33,444 shares of Kyverna Therapeutics worth $298 as of Q2 2026.
  • Banque Cantonale Vaudoise bought 2,912 Kyverna Therapeutics shares in Q2 2026, an estimated $25.9K.
  • Kyverna Therapeutics made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #592 holding.
  • Banque Cantonale Vaudoise first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Banque Cantonale Vaudoise's Kyverna Therapeutics position peaked at $263K in Q1 2026.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.